Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017549 · ClinicalTrials.gov registry record · NA
Post Market Study Using the Xoft Axxent System
A NA study, sponsored by Xoft.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01017549: Completed NA study, sponsored by Xoft.
NCT01017549 is a NA study that has completed, run by Xoft. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01017549, a NA study, has completed, sponsored by Xoft.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System.
Primary Outcome
Successful delivery of the radiation treatment defined as a total 34 Gy in a total of 10 fractions, 3.4 Gy per fraction. (Gray = GY is a measure of radiation dose delivered to tissue)
Interventions
- RADIATION Electronic brachytherapy (Axxent System)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-03-26 |
| Est. Completion | 2016-05-07 |
| Phase | NA |
What the finished NCT01017549 record still lists
NCT01017549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Electronic brachytherapy (Axxent System) is the first listed.
NCT01017549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01017549 about?
NCT01017549 is a clinical study titled "Post Market Study Using the Xoft Axxent System". The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System.
What is the current status of trial NCT01017549?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2007-03-26. Estimated completion is 2016-05-07.
What interventions are being tested in trial NCT01017549?
The interventions under investigation include: Electronic brachytherapy (Axxent System) (RADIATION).
Who is sponsoring clinical trial NCT01017549?
This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01017549's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI